The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors
Everolimus doses from 5 to 6 mg/day seem to be equally as effective as higher doses, but lower doses are potentially associated with less toxicity and lower costs. These findings support validation through a randomized clinical trial.
Authors
- Angelo Borsarelli Carvalho Brito (ORCID: https://orcid.org/0000-0001-9424-0010)
- Ana Luiza Silva
- Rui Weschenfelder
- Rachel P. Riechelmann (ORCID: https://orcid.org/0000-0002-0107-9617)
- Rodrigo Gomes Taboada (ORCID: https://orcid.org/0000-0001-5674-2669)
Institutions
- AC Camargo Hospital (BR)
- Hospital Moinhos de Vento (BR)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-08
- DOI
- https://doi.org/10.3390/cancers16223773
- Citations
- 3
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.16